2019
Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis
JAIRAM V, KANN BH, PARK HS, MICCIO JA, BECKTA JM, YU JB, PRABHU RS, GAO SJ, MEHTA MP, CURRAN WJ, BINDRA RS, CONTESSA JN, PATEL KR. Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research 2019, 39: 2911-2918. PMID: 31177129, DOI: 10.21873/anticanres.13420.Peer-Reviewed Original ResearchConceptsIntermediate-risk groupInferior overall survivalOverall survivalAdjuvant therapyLow-grade gliomasTumor sizePrognostic featuresMultivariate analysisPre-operative tumor sizeNational Cancer Database AnalysisNational Cancer DatabaseLow-risk patientsCohort of patientsKaplan-Meier methodPoor prognostic featuresGross total resectionHigh-risk groupPatterns of careAdditional prognostic featuresRTOG 9802Clinical factorsTotal resectionCancer DatabaseRisk groupsClinical classification
2016
Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy
Harder EM, Park HS, Chen Z, Decker RH. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy. Practical Radiation Oncology 2016, 6: e353-e359. PMID: 27156424, DOI: 10.1016/j.prro.2016.01.015.Peer-Reviewed Original ResearchConceptsMean lung doseStereotactic body radiation therapyRisk of gradeRadiation pneumonitisMultivariable logistic regressionBody radiation therapyDosimetric predictorsRadiation therapyMaximum doseLogistic regressionRP rateBest dosimetric predictorCardiac dosimetric parametersDose-volume predictorsPercent of lungVolume of lungGross tumor volumeBackward stepwise eliminationLung V10Lung doseMean doseTotal lungUnivariate analysisPulmonary volumesTumor volume
2015
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer
Park HS, Harder EM, Mancini BR, Decker RH. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2015, 10: 832-837. PMID: 25634007, DOI: 10.1097/jto.0000000000000484.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyBiological equivalent doseCentral tumor locationCell lung cancerOverall survivalTumor locationCentral tumorsLocal controlLung cancerBody radiotherapyPrimary non-small cell lung cancerNon-small cell lung cancerMultivariable logistic regression modelingMultivariable Cox regression modelingInoperable early stageProximal bronchial treeInferior overall survivalCox regression modelingKaplan-Meier analysisWorse overall survivalPeripheral tumor locationRegression modelingLogistic regression modelingAcute gradeCT1-2N0M0
2014
Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States
Rutter CE, Corso CD, Park HS, Mancini BR, Yeboa DN, Lester-Coll NH, Kim AW, Decker RH. Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States. Lung Cancer 2014, 85: 390-394. PMID: 25001510, DOI: 10.1016/j.lungcan.2014.06.013.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStereotactic body radiotherapyBody radiotherapyStage I non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerMultivariate analysisUse of SBRTLung stereotactic body radiotherapyLogistic regressionNational Cancer DatabasePercentage of patientsYear of diagnosisSmaller tumor sizeCell lung cancerMultivariate logistic regressionMedical inoperabilityMedical comorbiditiesInoperable patientsTumor sizeLung cancerCancer DatabaseEfficacious treatmentSBRT deliveryBiopsy